You're leaving Lundbeck Australia

You are now leaving Please note that the information contained in the site you are linking to may not be fully compliant with the Australian regulatory environment and that product related information should be checked against the corresponding Australian consumer medicine information or by asking your doctor. Any information provided should be discussed with your health care professional and does not replace the advice and treatment of your doctor.

Click here to leave


Our Commitment

Going Beyond the Pill

Global progress for people living with brain diseases requires a multifaceted approach. Beyond developing new and improved medical therapies, we strive to make a difference for patients, to increase support to affected families and to engage to create broader social acceptance of people living with brain diseases.
At Lundbeck, we are tirelessly dedicated to restoring brain health, so every person can be their best.

Brain disease currently affects more than 700 million people globally, representing 13% of the global disease burden.


We work tirelessly on restoring brain health because:


  • More than 70% of people living with brain disease experience discrimination
  • People living with brain disease live between 10-20 years less than healthy individuals
  • The World Health Organisation (WHO) estimates that the global economy loses about 1 trillion USD a year in productivity due to depression and anxiety alone.


“Depressed people can’t help themselves. They need help” Xue Bing, living with depression.


Our commitment is to empower patients to give them the tools and resources they need to understand their disease and its unfolding.


Our commitment is to continuously challenge the status quo and push our science further to make real differences for patients.


Our commitment is to families to bring evidence-based data, visibility and support to their work in managing a chronic disease.


Our commitment is to communities to end the stigma, fear, and silence that surrounds brain diseases.


We call this Progress in Mind.

Healthcare Professionals

Research and development (R&D) of new and improved treatments is at the core of what we do. We have state-of-theart research centers in Denmark and California, US, and more than 800 employees work in our R&D units. We fund independent research and collaborate closely with strategic partners all over the world. We provide high-quality and evidence-based medical education and training for healthcare professionals on neurology and psychiatry via the Lundbeck Institute seminars, publications and online campus, and through our Progress in Mind Resource Centre.

Strengthening Communities

Despite some improvements, discrimination against people with brain diseases continues to be a serious and pervasive social problem. Stigma operates on many levels from thepersonal to the professional. To this end, we take our position as specialists seriously and use our voice to raise awareness, challenge standards and increase opportunities for patients to participate more fully in their communities and networks.


We do this by actively sponsoring and participating in disease awareness, anti-stigma, and mental health promotioncampaigns, working with the international advocacy community.

For Patients and with Patients

Being diagnosed with a brain disease brings complex experiences. We aim to amplify patients’ voices and needs through our publications, events, engagement activities and partnerships with advocacy groups and patient organizations – together we carry the message further than any one single group can do alone.


To leverage the support of families, loved ones and carers, we work with caregivers and advocacy groups to support evidence generation and awareness campaigns on the value they bring to disease management.

Our Continued Responsibility

For more than 70 years, we’ve been pushing the boundaries of neuroscience. Even though research into the brain costs more, takes longer and fails at a higher rate than most othermedical research, we have not abandoned the psychiatric and neurological space. Indeed, with brain diseases sharply on the increase, it’s more important than ever that we accelerate our efforts. As one of the only global pharmaceutical companies to focus exclusively on brain diseases, we have demonstrated staying power, our specialist knowledge, and a comprehensive treatment approach.


Convinced that we can help improve the quality of life for people affected by brain disease and ever-mindful of this purpose, Lundbeck perseveres.